Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia

Journal of Cardiovascular Pharmacology

Volumn 18, Issue , 1991, Pages S22-S28

  Hashimoto, Hiroo ^a   Kanda, Akira ^a   Hubo, Hideo ^a   Tanaka, Makoto ^a  

^a Daüchi Pharmaceutical Company Limited ^*  (Japan)

Author keywords

Carvedilol; Duration of hypotensive effect; Experimental myocardial ischemia; 1 Blockade

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CARVEDILOL; DILTIAZEM; HYDRALAZINE; LABETALOL; NITROPRUSSIDE SODIUM; PHENTOLAMINE; PRAZOSIN; PROSTAGLANDIN F2 ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEART MUSCLE ISCHEMIA; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PH; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMAL; BLOOD PRESSURE; CARBAZOLES; CORONARY DISEASE; DOGS; FEMALE; HEART RATE; HYDROGEN-ION CONCENTRATION; MALE; PHENTOLAMINE; PROPANOLAMINES; RATS; RATS, INBRED SHR; RECEPTORS, ADRENERGIC, ALPHA; TIME FACTORS; VASODILATOR AGENTS;

EID: 0025790273     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199118041-00006     Document Type: Article

References (20)

1. Abshagen U. A new molecule with vasodilating and β-ad-renoceptor blocking properties. J Cardiovase Pharmacol 1987;10(suppl 11):S23-32.
2. Tanaka M, Masumura H. Tanaka S, Akashi A. Studies on the antihypertensive properties of carvedilol, a compound with β-blocking and vasodilating effects. J Cardiovase Pharmacol 1987; 10(suppl 11):S52-7.
3. Eggertsen R. Sivertsson R, Andren L. Hansson L. Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovase Pharmacol 1987; 10(suppl 11):S97-100.
4. Hashimoto H, Tanaka M. Kanda A. Akashi A. Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats. Drugs 1988;36(suppl 6):31-6.
5. Ogihara T, Goto Y. Yoshinaga K, et al. Dose-effect relationship of carvedilol in essential hypertension. An open study. Drugs 1988;36(suppl 6):75-81.
6. McPhiIlips JJ. Schwemer GT, Scott Dl, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 1988;36(suppl 61:82-91.
7. Rittinghausen R. Response rate with respect to the blood pressure-lowering effect of the vasodilating and β-blocking agent carvedilol. Drugs 1988;36(suppl 61:92-101.
8. Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Col-indres RE, Powell JR. Clinical pharmacology of carvedilol in normal volunteers. Clin Pharmacol Ther 1987;41:31-44.
9. Seki N, Nagao T. Komori K, Suzuki H. Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein. J Pharmacol Exp Ther 1988;246:1116-22.
10. Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol (BM 14.190) a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol 1985:56:35-40.
11. Rodrigues EA, Lahiri A, Hughes LO, Kohli RS, Raftery EB. Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity. Am J Cardiol 1986;58:916-21.
12. Abiko Y, Ichihara K, Sakai K, Sashida H, Ishibashi T. Method for evaluating antianginal drugs in experimental animals; assessment of myocardial ischemia by myocardial pH. Methods Find Exp Clin Pharmacol 1986;8:271-8.
13. Su DF, Cerutti C, Barres C, Vincent M, Sassard J. Blood pressure and baroreflex sensitivity in conscious hypertensive rats of Lyon strain. Am J Physiol 1986;251:H1111-7.
14. Sponer G, Strein K, Müller-Beckmann B, Bartsch W. Studies on the mode of vasodilating action of carvedilol. J Cardiovasc Pharmacol 1987;10(suppl 11):S42-8.
15. Gevers W. Generation of protons by metabolic processes in heart cells. J Mol Cell Cardiol 1977;9:867-74.
16. Khuri SF, Kloner RA, Karaffa SA, et al. The significance of the late fall in myocardial Pco2 and its relationship to myocardial pH after regional coronary occlusion in the dog. Circ Res 1985;56:537-47.
17. 2during regional ischemia in the dog heart. Arch Int Pharmacodyn Ther 1983;264:274-89.
18. Ichihara K, Sakai K, Abiko Y. Effect of nifedipine and ni-Iudipine on myocardial pH in the ischemic canine heart. Arch Int Pharmaeodyn Ther 1986;280:58-73.
19. Izumi T, Sakai K, Abiko Y. Effect of sotalol on ischemic myocardial pH in the dog heart. Naunyn Schmiedebergs Arch Pharmacol 1982;318:340-3.
20. Sakai K, Abiko Y. Attenuation by atenolol of myocardial acidosis during ischemia in dogs: Contribution of beta-1 adrenoceptors to myocardial acidosis. J Pharmacol Exp Ther 1984;232:810-6.